[A20-53] Fostamatinib (chronic immune thrombocytopenia) - Benefit assessment according to §35a Social Code Book V
Last updated 01.10.2020
Project no.:
A20-53
Commission:
Commission awarded on 08.07.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Haematology
Indication:
Adults with chronic immune thrombocytopenia who are refractory to other treatments
Result of dossier assessment:
Added benefit not proven due to lack of suitable study data
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.